Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression

Cell Reports

Volumn 13, Issue 7, 2015, Pages 1418-1431

  Mottok, Anja ^a,b   Woolcock, Bruce ^a   Chan, Fong Chun ^a,c   Tong, King Mong ^a   Chong, Lauren ^a,c   Farinha, Pedro ^a   Telenius, Adèle ^a   Chavez, Elizabeth ^a   Ramchandani, Suvan ^a   Drake, Marie ^a   Boyle, Merrill ^a   Ben Neriah, Susana ^a   Scott, David W ^a   Rimsza, Lisa M ^d   Siebert, Reiner ^e   Gascoyne, Randy D ^a,b   Steidl, Christian ^a,b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRANSACTIVATOR PROTEIN; HLA ANTIGEN CLASS 2; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN;

AGAR GEL ELECTROPHORESIS; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL LINE; CIITA GENE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MAPPING; GENE MUTATION; GENE REARRANGEMENT; GENETIC DISORDER; GENOMIC INSTABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTRON; LARGE CELL LYMPHOMA; LYMPHOBLASTOID CELL LINE; MALE; MISSENSE MUTATION; NONSENSE MUTATION; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIMARY MEDIASTINAL LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; RNA SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC HYPERMUTATION; TISSUE MICROARRAY; TUMOR ESCAPE; TUMOR GENE; TUMOR MICROENVIRONMENT; CELL LINE; DNA MUTATIONAL ANALYSIS; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; MEDIASTINUM TUMOR; METABOLISM;

CELL LINE; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTRONS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MEDIASTINAL NEOPLASMS; NUCLEAR PROTEINS; POINT MUTATION; SEQUENCE DELETION; TRANS-ACTIVATORS; TUMOR ESCAPE;

EID: 84947311621     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.10.008     Document Type: Article

References (49)

1. Armand P., Nagler A., Weller E.A., Devine S.M., Avigan D.E., Chen Y.-B., Kaminski M.S., Holland H.K., Winter J.N., Mason J.R., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013, 31:4199-4206.
2. Bentz M., Barth T.F.E., Brüderlein S., Bock D., Schwerer M.J., Baudis M., Joos S., Viardot A., Feller A.C., Müller-Hermelink H.-K., et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer 2001, 30:393-401.
3. Bödör C., Bognár A., Reiniger L., Szepesi A., Tóth E., Kopper L., Matolcsy A. Aberrant somatic hypermutation and expression of activation-induced cytidine deaminase mRNA in mediastinal large B-cell lymphoma. Br. J. Haematol. 2005, 129:373-376.
4. Bontron S., Ucla C., Mach B., Steimle V. Efficient repression of endogenous major histocompatibility complex class II expression through dominant negative CIITA mutants isolated by a functional selection strategy. Mol. Cell. Biol. 1997, 17:4249-4258.
5. Camacho-Carvajal M.M., Klingler S., Schnappauf F., Hake S.B., Steimle V. Importance of class II transactivator leucine-rich repeats for dominant-negative function and nucleo-cytoplasmic transport. Int. Immunol. 2004, 16:65-75.
6. Challa-Malladi M., Lieu Y.K., Califano O., Holmes A.B., Bhagat G., Murty V.V., Dominguez-Sola D., Pasqualucci L., Dalla-Favera R. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
7. Cycon K.A., Clements J.L., Holtz R., Fuji H., Murphy S.P. The immunogenicity of L1210 lymphoma clones correlates with their ability to function as antigen-presenting cells. Immunology 2009, 128(1, Suppl):e641-e651.
8. Diepstra A., van Imhoff G.W., Karim-Kos H.E., van den Berg A., te Meerman G.J., Niens M., Nolte I.M., Bastiaannet E., Schaapveld M., Vellenga E., Poppema S. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J. Clin. Oncol. 2007, 25:3101-3108.
9. Green M.R., Kihira S., Liu C.L., Nair R.V., Salari R., Gentles A.J., Irish J., Stehr H., Vicente-Dueñas C., Romero-Camarero I., et al. Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation. Proc. Natl. Acad. Sci. USA 2015, 112:E1116-E1125.
10. Greiner A., Tobollik S., Buettner M., Jungnickel B., Herrmann K., Kremmer E., Niedobitek G. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J. Pathol. 2005, 205:541-547.
11. Gunawardana J., Chan F.C., Telenius A., Woolcock B., Kridel R., Tan K.L., Ben-Neriah S., Mottok A., Lim R.S., Boyle M., et al. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. Nat. Genet. 2014, 46:329-335.
12. Jiang Y., Soong T.D., Wang L., Melnick A.M., Elemento O. Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. PLoS ONE 2012, 7:e40332.
13. Joos S., Menz C.K., Wrobel G., Siebert R., Gesk S., Ohl S., Mechtersheimer G., Trümper L., Möller P., Lichter P., Barth T.F. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 2002, 99:1381-1387.
14. Khodabakhshi A.H., Morin R.D., Fejes A.P., Mungall A.J., Mungall K.L., Bolger-Munro M., Johnson N.A., Connors J.M., Gascoyne R.D., Marra M.A., et al. Recurrent targets of aberrant somatic hypermutation in lymphoma. Oncotarget 2012, 3:1308-1319.
15. Leithäuser F., Bäuerle M., Huynh M.Q., Möller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 2001, 98:2762-2770.
16. Li J., Jørgensen S.F., Maggadottir S.M., Bakay M., Warnatz K., Glessner J., Pandey R., Salzer U., Schmidt R.E., Perez E., et al. Association of CLEC16A with human common variable immunodeficiency disorder and role in murine B cells. Nat. Commun. 2015, 6:6804.
17. Liso A., Capello D., Marafioti T., Tiacci E., Cerri M., Distler V., Paulli M., Carbone A., Delsol G., Campo E., et al. Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood 2006, 108:1013-1020.
18. Liu M., Duke J.L., Richter D.J., Vinuesa C.G., Goodnow C.C., Kleinstein S.H., Schatz D.G. Two levels of protection for the B cell genome during somatic hypermutation. Nature 2008, 451:841-845.
19. Loeffler M., Kreuz M., Haake A., Hasenclever D., Trautmann H., Arnold C., Winter K., Koch K., Klapper W., Scholtysik R., et al. Genomic and epigenomic co-evolution in follicular lymphomas. Leukemia 2015, 29:456-463. HaematoSys-Project.
20. Lohsen S., Majumder P., Scharer C.D., Barwick B.G., Austin J.W., Zinzow-Kramer W.M., Boss J.M. Common distal elements orchestrate CIITA isoform-specific expression in multiple cell types. Genes Immun. 2014, 15:543-555.
21. Masternak K., Muhlethaler-Mottet A., Villard J., Zufferey M., Steimle V., Reith W. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev. 2000, 14:1156-1166.
22. Melzner I., Weniger M.A., Bucur A.J., Brüderlein S., Dorsch K., Hasel C., Leithäuser F., Ritz O., Dyer M.J., Barth T.F., Möller P. Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein. Int. J. Cancer 2006, 118:1941-1944.
23. Mestre C., Rubio-Moscardo F., Rosenwald A., Climent J., Dyer M.J.S., Staudt L., Pinkel D., Siebert R., Martinez-Climent J.A. Homozygous deletion of SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC microarrays. Leukemia 2005, 19:1082-1084.
24. Migliazza A., Martinotti S., Chen W., Fusco C., Ye B.H., Knowles D.M., Offit K., Chaganti R.S., Dalla-Favera R. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl. Acad. Sci. USA 1995, 92:12520-12524.
25. Mortara L., Frangione V., Castellani P., De Lerma Barbaro A., Accolla R.S. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions. Int. Immunol. 2009, 21:655-665.
26. Mottok A., Renné C., Willenbrock K., Hansmann M.-L., Bräuninger A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 2007, 110:3387-3390.
27. Mottok A., Renné C., Seifert M., Oppermann E., Bechstein W., Hansmann M.-L., Küppers R., Bräuninger A. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. Blood 2009, 114:4503-4506.
28. Muhlethaler-Mottet A., Otten L.A., Steimle V., Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 1997, 16:2851-2860.
29. Müschen M., Re D., Jungnickel B., Diehl V., Rajewsky K., Küppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J. Exp. Med. 2000, 192:1833-1840.
30. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., Staudt L.M. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006, 441:106-110.
31. Okosun J., Bödör C., Wang J., Araf S., Yang C.-Y., Pan C., Boller S., Cittaro D., Bozek M., Iqbal S., et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 2014, 46:176-181.
32. Pasqualucci L., Migliazza A., Fracchiolla N., William C., Neri A., Baldini L., Chaganti R.S.K., Klein U., Küppers R., Rajewsky K., Dalla-Favera R. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc. Natl. Acad. Sci. USA 1998, 95:11816-11821.
33. Pasqualucci L., Neumeister P., Goossens T., Nanjangud G., Chaganti R.S.K., Küppers R., Dalla-Favera R. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature 2001, 412:341-346.
34. Piskurich J.F., Gilbert C.A., Ashley B.D., Zhao M., Chen H., Wu J., Bolick S.C., Wright K.L. Expression of the MHC class II transactivator (CIITA) type IV promoter in B lymphocytes and regulation by IFN-γ. Mol. Immunol. 2006, 43:519-528.
35. Popov S.W., Moldenhauer G., Wotschke B., Brüderlein S., Barth T.F., Dorsch K., Ritz O., Möller P., Leithäuser F. Target sequence accessibility limits activation-induced cytidine deaminase activity in primary mediastinal B-cell lymphoma. Cancer Res. 2007, 67:6555-6564.
36. Rimsza L.M., Roberts R.A., Miller T.P., Unger J.M., LeBlanc M., Braziel R.M., Weisenberger D.D., Chan W.C., Muller-Hermelink H.K., Jaffe E.S., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004, 103:4251-4258.
37. Roberts R.A., Wright G., Rosenwald A.R., Jaramillo M.A., Grogan T.M., Miller T.P., Frutiger Y., Chan W.C., Gascoyne R.D., Ott G., et al. Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival. Blood 2006, 108:311-318.
38. Rosenwald A., Wright G., Leroy K., Yu X., Gaulard P., Gascoyne R.D., Chan W.C., Zhao T., Haioun C., Greiner T.C., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J. Exp. Med. 2003, 198:851-862.
39. Savage K.J., Monti S., Kutok J.L., Cattoretti G., Neuberg D., De Leval L., Kurtin P., Dal Cin P., Ladd C., Feuerhake F., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871-3879.
40. Scholl T., Mahanta S.K., Strominger J.L. Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. Proc. Natl. Acad. Sci. USA 1997, 94:6330-6334.
41. Steidl C., Gascoyne R.D. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood 2011, 118:2659-2669.
42. Steidl C., Shah S.P., Woolcock B.W., Rui L., Kawahara M., Farinha P., Johnson N.A., Zhao Y., Telenius A., Neriah S.B., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-381.
43. Steimle V., Otten L.A., Zufferey M., Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993, 75:135-146.
44. Swerdlow S., Campo E., Harris N., Jaffe E. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008, IARC Press, Lyon, France. Fourth Edition.
45. Twa D.D.W., Chan F.C., Ben-Neriah S., Woolcock B.W., Mottok A., Tan K.L., Slack G.W., Gunawardana J., Lim R.S., McPherson A.W., et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014, 123:2062-2065.
46. Twa D.D.W., Mottok A., Chan F.C., Ben-Neriah S., Woolcock B.W., Tan K.L., Mungall A.J., McDonald H., Zhao Y., Lim R.S., et al. Recurrent genomic rearrangements in primary testicular lymphoma. J. Pathol. 2015, 236:136-141.
47. Wang K., Li M., Hadley D., Liu R., Glessner J., Grant S.F.A., Hakonarson H., Bucan M. PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res. 2007, 17:1665-1674.
48. Wessendorf S., Barth T.F.E., Viardot A., Mueller A., Kestler H.A., Kohlhammer H., Lichter P., Bentz M., Döhner H., Möller P., Schwaenen C. Further delineation of chromosomal consensus regions in primary mediastinal B-cell lymphomas: an analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 2007, 21:2463-2469.
49. Yau C., Mouradov D., Jorissen R.N., Colella S., Mirza G., Steers G., Harris A., Ragoussis J., Sieber O., Holmes C.C. A statistical approach for detecting genomic aberrations in heterogeneous tumor samples from single nucleotide polymorphism genotyping data. Genome Biol. 2010, 11:R92.